{
    "clinical_study": {
        "@rank": "73809", 
        "acronym": "VESTOR", 
        "arm_group": {
            "arm_group_label": "TORISEL", 
            "arm_group_type": "Experimental", 
            "description": "Torisel"
        }, 
        "brief_summary": {
            "textblock": "In the absence of standard treatment in this indication, this test evaluates a new drug type\n      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and\n      survival."
        }, 
        "brief_title": "Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In the absence of standard treatment in this indication, this test evaluates a new drug type\n      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and\n      survival. This study will also search for genes involved in the response to treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women of at least 18 years of age\n\n          -  Histologically proven Bladder cancer\n\n          -  Locally advanced or metastatic disease (stage IV)\n\n          -  Functional status (ECOG / OMS) \u2264 2\n\n          -  Relapse after first-line chemotherapy\n\n          -  Measurable lesions (RECIST criteria)\n\n          -  Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.\n\n          -  Biological levels :\n\n          -  Neutrophil count >1,5.109/L.\n\n          -  Platelets >100.109/L\n\n          -  Total serum bilirubin < 1.5 \u00d7 ULN\n\n          -  Clearance of cr\u00e9atinine 40 ml/mm\n\n          -  If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase\n             (AST) <2.5 \u00d7 ULN\n\n          -  With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5 \u00d7\n             ULN\n\n          -  Signed informed consent France only : Patients affiliated to a social security\n             program\n\n        Exclusion Criteria:\n\n          -  Presence of uncontrolled metastatic brain or meningeal tumours\n\n          -  Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion\n\n          -  Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or\n             polysorbate 80 or to their excipients\n\n          -  Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma\n             curatively treated) or incidental (\u2264 pT2) prostate cancer found on a radical\n             cystoprostatectomy material\n\n          -  Auto-immune pathology, psychiatric or neurological disorder\n\n          -  Any unstable medical condition\n\n          -  Unstable cardiac disease\n\n          -  Severe renal failure\n\n          -  Unstable diabetes\n\n          -  Pregnancy\n\n          -  Patient enrolled in another therapeutic clinical trial\n\n          -  Patient unable to follow and comply with the study procedures because of any\n             geographical, social or medical condition\n\n          -  Patient partially or totally deprived of his civil rights"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827943", 
            "org_study_id": "IB2009-08"
        }, 
        "intervention": {
            "arm_group_label": "TORISEL", 
            "description": "Temsirolimus", 
            "intervention_name": "TORISEL", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Relapsed bladder cancer", 
        "lastchanged_date": "April 9, 2013", 
        "link": {
            "description": "Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Herv\u00e9 WALLERAND"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "CHU de Bordeaux"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Florence JOLY"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }, 
                    "name": "Centre Fran\u00e7ois Baclesse"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hakim Mahammedi"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "St\u00e9phane CULINE"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "CHU Henri Mondor"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Aude FLECHON"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lionel VEDRINE"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75230"
                    }, 
                    "name": "H\u00f4pital d'instruction des arm\u00e9es du Val-de-Gr\u00e2ce"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christian PFISTER"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76031"
                    }, 
                    "name": "CHU de Rouen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christine CHEVREAU"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bernard MALAVAUD"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU de Toulouse"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel \u00ae) in Second Line Therapy for Patients With Advanced Bladder Cancer", 
        "overall_contact": {
            "email": "houede@bergonie.org", 
            "last_name": "Nadine HOUEDE, MD", 
            "phone": "0556333333"
        }, 
        "overall_contact_backup": {
            "email": "mathoulin@bergonie.org", 
            "last_name": "Simone MATHOULIN-PELISSIER, PU-PH", 
            "phone": "0556333333"
        }, 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "Nadine HOUEDE, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the efficacy of Temsirolimus (Torisel \u00ae) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment", 
            "measure": "Evaluation of the efficacy of Temsirolimus (Torisel \u00ae) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment", 
            "safety_issue": "No", 
            "time_frame": "12/2013 (2 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Progression free survival\nDuration of response\nTime to progression\nOverall survival\nQuality of life", 
            "measure": "\u2022 Progression free survival  \u2022 Duration of response \u2022 Time to progression \u2022 Overall survival \u2022 Quality of life", 
            "safety_issue": "No", 
            "time_frame": "12/2013 (2 months)"
        }, 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "collaborator": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}